-
Farkas' FDA Departure Could Signal 'Imminent Decision' For Eteplirsen
Wednesday, September 14, 2016 - 10:08am | 304Read More...Checks indicate that Dr. Ronald Farkas has left the FDA and his name no longer appeared in the HHS employee directory. Oppenheimer’s Michelle Gilson said this was “a positive signal for eteplirsen approval” and maintained an Outperform rating on Sarepta Therapeutics Inc (...
-
Mirna Therapeutics Could See A Clinical Hold On MRX34
Tuesday, August 16, 2016 - 2:28pm | 361Read More...Oppenheimer has warned that Mirna Therapeutics Inc (NASDAQ: MIRN) could face a clinical hold on its MRX34 on safety concerns. The company "disclosed another patient death from an immune-mediated SAE in Phase 1 study of MRX34 in multiple advanced cancers, deemed possibly related to MRX34 therapy by...
-
This Is A Near-Term Driver At CytRX
Tuesday, May 5, 2015 - 12:45pm | 324Read More...Oppenheimer commented on CytRx Corporation (NASDAQ: CYTR) Tuesday and maintained an Outperform rating and $10 price target. The research note followed the company’s Q1 results and its posting EPS of $(0.31) versus expectations of $(0.20). Analysts Christopher Marai and Michelle Gilson...
